Gilead Sciences
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).www.gilead.com
98
MENTIONS
49
EPISODES
43
PODCASTS
Search complete. 98 mentions across 49 episodes found for "Gilead Sciences".
Sep 23, 2026
J. Stephen MorrisonHOST
That was announced September eighteenth, just a couple months before, uh, the, um, uh, Zipline partnership was announced.
J. Stephen MorrisonHOST
And the Lenyaprevir one was to expand the delivery of, of the prophylaxis prep, uh, uh, anti-HIV drug, uh, that involves Gilead Sciences, the Department of State, and the Global Fund.
J. Stephen MorrisonHOST
And we hosted them here in April, the leadership here, much as we're hosting you today.
J. Stephen MorrisonHOST
So this is a follow-on to something that was quite successful then, and we hosted, uh, the, the organizers of the Lenyaprevir at the Rio, uh, de Janeiro International AIDS Conference.
David LortscherGUEST
It's Intuitive Surgical.
David LortscherGUEST
When you think about the second most powerful, biggest healthcare company that was founded in the past four decades, it's Gilead, also founded by a physician, co-founded.
David LortscherGUEST
Number four, number five, Regeneron.
David LortscherGUEST
You know, all the way down the list, the top 100 most successful startups, 51% of them had a physician founder.
Rose ScottHOST
We'll begin today's special with the release of the sixth annual State of HIV Stigma Report.
Rose ScottHOST
It's from the organization GLAAD in partnership with Gilead Sciences.
Rose ScottHOST
Now, this report tracks knowledge and attitudes around HIV and HIV stigma and It also examines how people throughout the U.S. understand, talk about, and engage with HIV in the United States.
Rose ScottHOST
Jarrell Hartnett is an Associate Director of Education and Advocacy at GLAAD and the author of GLAAD's six-annual State of HIV Sticker Report.
Nina SchwalbeGUEST
Great, thank you so much for inviting me here.
Nina SchwalbeGUEST
Just a huge shout out to PrEP4ALL for your recent letter on the Preventive Task Force and how we need real expertise in that, and your dogged pursuit of Gilead's price gouging.
Nina SchwalbeGUEST
You know, American taxpayers fund the science, Gilead gets the patent, and we get the bill.
Nina SchwalbeGUEST
So thank you for that.
Nina SchwalbeGUEST
So I'm an L, LGBTQ+, just want to shout that out.
Nina SchwalbeGUEST
So that's what brings me here.
Jeremiah JohnsonMODERATOR
Thank you so much, Nina.
Jeremiah JohnsonMODERATOR
And I'm glad our work on Gilead has gotten some attention.
Loren LoRosaHOST
...
Loren LoRosaHOST
Love Lately with Lauren LaRosa in partnership with Gilead Sciences.
CiaraSOUNDBITE_SPEAKER
Yes.
CiaraSOUNDBITE_SPEAKER
We are diving into everything women are talking about.
Alex MercerHOST
It's been a busy week in pharma and biotech.
Maya PatelHOST
And Gilead started preparing access to a once-yearly HIV prevention shot before that formulation has results.
Maya PatelHOST
We'll separate those early commitments from the clinical and regulatory progress already in hand.
Alex MercerHOST
Welcome to the Pharma Closeout Week in Review for Sunday, September twentieth.
8 MINS LATER
Maya PatelHOST
We appreciate you listening.
Alex MercerHOST
Now to HIV prevention.
Alex MercerHOST
Gilead is preparing supply for a longer acting version of lenacapavir.
Alex MercerHOST
Twice yearly dosing is already approved.
Sarah HagiHOST
His already fragile mental state continues to deteriorate, fueled by widespread conspiracy theories.
Sarah HagiHOST
Carl becomes convinced that a company called Gilead Sciences is going to make the COVID cure and obsessively researches them for weeks.
Sarah HagiHOST
He puts huge seven-figure option bets on Gilead's stock going up, while also betting that the S&P 500 will keep falling.
Sarah HagiHOST
According to court documents, Carl believes he's hedging the market, saying, quote,
Mike SantoliHOST
Yeah, the stocks basically trade on your next act after this.
Mike SantoliHOST
I mean, you could just go back and look at Gilead.
Mike SantoliHOST
right? Oh, Hep C.
Mike SantoliHOST
They kind of cure Hep C. It's this massive market, and the stock gets super cheap because it's like, okay, we got it.
Lauren LaRosaSOUNDBITE_SPEAKER
The I Heart Radio Music Festival.
Lauren LaRosaSOUNDBITE_SPEAKER
We are here to announce our brand new audio series, Together, Love Lately with Laura La Rosa, in partnership with Gilead Sciences.
Contessa MetcalfeSOUNDBITE_SPEAKER
Yes, we are diving into everything women are talking about.
Contessa MetcalfeSOUNDBITE_SPEAKER
Yes, dating, relationships, and of course, the importance of women's sexual health.
Peter JonesHOST
So some of you may know that I am the Mick Hitchcock PhD endowed chair in medical biochemistry at the University of Nevada, Reno.
Peter JonesHOST
And in addition to being a wonderful philanthropist, you know, Mick actually is a scientist and he ran Gilead, which is a large pharmaceutical company for about 23 years, I believe.
Peter JonesHOST
And they were a small company up to, gosh, tens of thousands of employees, developed Tamiflu, some of the hepatitis, some AIDS therapies, and some really done some amazing stuff.
Peter JonesHOST
And he really is dedicating his life now to the next generation of scientists, and in this case, journalists.
39 more episodes mention Gilead Sciences.
Create an account to see the whole feed, search across every transcript, and follow the entities you care about.